Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11211791 | 0.76 | L3MBTL1 (0.61) | L3MBTL1SMN1; SMN2GAALMNAPOLB | |
| SCHEMBL11919296 | 0.76 | L3MBTL1 (0.61) | L3MBTL1SMN1; SMN2GAALMNAPOLB | |
| SCHEMBL31558537 | 0.76 | L3MBTL1 (0.61) | L3MBTL1SMN1; SMN2GAALMNAPOLB | |
| SCHEMBL11059491 | 0.72 | L3MBTL1 (0.57) | L3MBTL1SMN1; SMN2GAALMNAPOLB | |
| SCHEMBL5305104 | 0.71 | SMN1; SMN2 (0.62) | L3MBTL1SMN1; SMN2GAALMNAPOLB | |
| SCHEMBL9879120 | 0.71 | HTT (0.63) | L3MBTL1LMNAKDM4ECYP2C9CYP2C19 | |
| SCHEMBL6959750 | 0.70 | — | — | |
| SCHEMBL4417500 | 0.70 | L3MBTL1 (0.53) | L3MBTL1SMN1; SMN2GAAPOLBKDM4E | |
| SCHEMBL8720515 | 0.69 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2GAALMNAKDM4E | |
| SCHEMBL12036847 | 0.68 | L3MBTL1 (0.52) | L3MBTL1GAALMNAKDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| CN-110372720-B | Kinase inhibitor | 锦州奥鸿药业有限责任公司 | 2021-03-05 | — | — | CN | disclosed |
| EP-3149008-B1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2018-12-12 | — | — | EP | disclosed |
| US-10087195-B2 | Certain protein kinase inhibitors | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-10-02 | — | — | US | disclosed |
| US-9944645-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170267696-A1 | CERTAIN PROTEIN KINASE INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| EP-3149008-A1 | CERTAIN PROTEIN KINASE INHIBITORS | Shanghai Fochon Pharmaceutical Co. Ltd (CN) | 2017-04-05 | — | — | EP | disclosed |
| US-20160326178-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2016-11-10 | — | — | US | disclosed |
| EP-3034075-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Holdings Corporation (US) | 2016-06-22 | — | — | EP | disclosed |
| CN-103664873-B | As 3-(3-amino piperidine-1-yl)-5-oxo-1 of DPP IV (DPP-IV) inhibitor, 2,4-pyrrolotriazine derivatives | 深圳信立泰药业股份有限公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20110144113-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2011-06-16 | — | — | US | disclosed |
| US-20110136781-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-7915408-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-7767675-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100130467-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2010-05-27 | — | — | US | disclosed |
| US-7683060-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2007017114-A1 | NEW SUBSTITUTED AZATHYMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES | MERLION PHARMACEUTICALS SA (CH) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087195-B2 | Certain protein kinase inhibitors | CDK4, CDK6, CDK2 | L3MBTL1 3347/4885SMN1; SMN2 3875/4885GAA 2106/4885 |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | L3MBTL1 1639/4885SMN1; SMN2 4495/4885GAA 3967/4885 |
| US-20160326178-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | L3MBTL1 2276/4885SMN1; SMN2 3371/4885GAA 4095/4885 |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | L3MBTL1 925/4885SMN1; SMN2 3598/4885GAA 920/4885 |
| US-20100130467-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | L3MBTL1 1639/4885SMN1; SMN2 4495/4885GAA 3967/4885 |
| US-20110136781-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | L3MBTL1 2276/4885SMN1; SMN2 3371/4885GAA 4095/4885 |
| US-20170267696-A1 | CERTAIN PROTEIN KINASE INHIBITORS | CDK4, CDK6, CDK2 | L3MBTL1 3347/4885SMN1; SMN2 3875/4885GAA 2106/4885 |
| US-20110144113-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | L3MBTL1 1639/4885SMN1; SMN2 4495/4885GAA 3967/4885 |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | L3MBTL1 2276/4885SMN1; SMN2 3371/4885GAA 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.